Preliminary evidence for biologic activity of toceranib phosphate (Palladia<sup>®</sup>) in solid tumours

London, Cheryl A.; Mathie, Tamra; Stingle, Nicole; Clifford, Craig; Haney, Siobhan; Klein, Mary K.; Beaver, Linda; Vickery, Kate; Vail, David M.; Hershey, Betsey; Ettinger, Stephen J.; Vaughan, Andrew T M; Alvarez, Francisco; Hillman, Lorin A.; Kiselow, Mike; Thamm, Douglas H.; Higginbotham, Mary Lynn; Gauthier, Meredith J.; Krick, Erika; Phillips, Brenda; LaDue, Tracy; Jones, Pamela D; Bryan, Jeffrey N.; Gill, Virginia; Novasad, Andrew; Fulton, Lisa; Carreras, Janet K.; McNeill, Conor J.; Henry, Carolyn J.; Gillings, Sarah L

doi:10.1111/j.1476-5829.2011.00275.x

Cited by 206 publications

(316 citation statements)

References 25 publications

Supporting

Mentioning

287

Contrasting

Unclassified

Order By: Relevance

“…For dogs with measurable disease, as in previous publications describing the use of toceranib in dogs, clinical benefit (CB) was determined by best response to therapy and was defined as a complete response (CR) or partial response (PR) of any duration, or stable disease (SD) of at least ten weeks in duration [30]. …”

Section: Methodsmentioning

confidence: 99%

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

et al. 2018

View full text Add to dashboard Cite

BackgroundEffective treatment options for inoperable, metastatic, or recurrent canine pheochromocytomas are lacking. In humans, specific germline mutations exist that drive the development of pheochromocytomas. Pharmaceutical blockade of these abnormalities with small molecule inhibitors are an effective treatment strategy. Similar mutations may exist in the dog, and thus, treatment with similar small molecule inhibitors may provide a survival advantage. The purpose of this study was to assess the role of toceranib phosphate in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas.ResultsRetrospectively, medical records of dogs that had a diagnosis or suspect diagnosis of a pheochromocytoma were reviewed for information regarding response to toceranib phosphate and overall outcome. Five dogs were identified that fit the inclusion criteria. All five experienced clinical benefit (1 partial response, 4 stable disease). Progression-free interval (PFI) for the dog with the partial response was 61 weeks. PFI for the two dogs with stable measurable disease were 36 weeks and 28 weeks. PFI in the two dogs with stable metastatic disease were at least 11 weeks and 18 weeks.ConclusionsBased on this limited series of dogs, the results suggest that toceranib may have biological activity in dogs with primary and metastatic pheochromocytomas. Larger studies are needed to define the use and response to toceranib in dogs with gross, microscopic, and metastatic pheochromocytoma.

show abstract

Section: Methodsmentioning

confidence: 99%

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Adjunctive therapies such as chemotherapy or radiation therapy can be considered depending on whether metastases are present or absent. Multiple studies [12][13][14][15][16] have described various primary and adjunctive therapy options for dogs with ASACs; however, inherent differences in study populations, numbers of patients evaluated, outcome measures, and long-term follow-up make it difficult to compare results or recommend particular definitive or adjunctive therapies.…”

mentioning

confidence: 98%

Surgical excision of anal sac apocrine gland adenocarcinomas with and without adjunctive chemotherapy in dogs: 42 cases (2005–2011)

Potanas¹,

Padgett²,

Gamblin³

2015

javma

View full text Add to dashboard Cite

Objective-To identify variables associated with prognosis in dogs undergoing surgical excision of anal sac apocrine gland adenocarcinomas (ASACs) with and without adjunctive chemotherapy. Design-Retrospective case series. Animals-42 dogs with ASACs. Procedures-Information on signalment, clinical signs, diagnostic procedures, surgical procedures, adjunctive therapies, survival time, and disease-free interval was obtained from the medical records. Results-Survival time was significantly associated with the presence of sublumbar lymphadenopathy and sublumbar lymph node extirpation, with median survival time significantly shorter for dogs with sublumbar lymphadenopathy (hazard ratio, 2.31) than for those without and for dogs that underwent lymph node extirpation (hazard ratio, 2.31) than for those that did not. Disease-free interval was significantly associated with the presence of sublumbar lymphadenopathy, lymph node extirpation, and administration of platinum-containing chemotherapeutic agents, with median disease-free interval significantly shorter for dogs with sublumbar lymphadenopathy (hazard ratio, 2.47) than for those without, for dogs that underwent lymph node extirpation (hazard ratio, 2.47) than for those that did not, and for dogs that received platinum-containing chemotherapeutic agents (hazard ratio, 2.69) than for those that did not. Survival time and disease-free interval did not differ among groups when dogs were grouped on the basis of histopathologic margins (complete vs marginal vs incomplete excision). Conclusions and Clinical Relevance-Results suggested that in dogs with ASAC undergoing surgical excision, the presence of sublumbar lymphadenopathy and lymph node extirpation were both negative prognostic factors. However, completeness of surgical excision was not associated with survival time or disease-free interval.

show abstract

“…However, a recent study performed in dogs with solid tumours did not show any obvious evidence (London and others 2012). Recently, Marcinowska and others (2013) described a dog with lymphangiosarcoma in the caudal mammary gland treated with MC (chlorambucil, meloxicam and TP) after excisional surgery and doxorubicin therapy, resulting in a regression of the tumour and stable disease for 14 months.…”

Section: Discussionmentioning

confidence: 99%

Caudoventral abdominal lymphangiosarcoma in a cat treated with metronomic chemotherapy

Castro‐López¹,

Bermúdez²,

Martínez³

et al. 2013

Vet Record Case Reports

View full text Add to dashboard Cite

A 10‐year‐old, male neutered domestic shorthair cat was referred for reddish discolouration of its abdominal skin with serosanguineous discharge. The affected skin was bruised, nodular and had fluid‐filled cavities. It was painful on palpation. A final diagnosis of lymphangiosarcoma was made by prospero‐related homeobox gene‐1 (PROX‐1) immunohistochemistry. Metronomic chemotherapy treatment was instaured with toceranib phosphate, chlorambucil and meloxicam. Partial remission was achieved at 18 days and stable disease was maintained for 36 days (survival time: 54 days). Afterward, the tumour began to regrow aggressively and the patient developed anorexia; owners elected for euthanasia. Total survival time achieved was 63 days. To the authors’ knowledge, this is the first case report of feline caudoventral abdominal lymphangiosarcoma treated with metronomic chemotherapy.

show abstract

Preliminary evidence for biologic activity of toceranib phosphate (Palladia^®) in solid tumours

Cited by 206 publications

References 25 publications

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

Surgical excision of anal sac apocrine gland adenocarcinomas with and without adjunctive chemotherapy in dogs: 42 cases (2005–2011)

Caudoventral abdominal lymphangiosarcoma in a cat treated with metronomic chemotherapy

Contact Info

Product

Resources

About

Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours

Cited by 206 publications

References 25 publications

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

Surgical excision of anal sac apocrine gland adenocarcinomas with and without adjunctive chemotherapy in dogs: 42 cases (2005–2011)

Caudoventral abdominal lymphangiosarcoma in a cat treated with metronomic chemotherapy

Contact Info

Product

Resources

About

Preliminary evidence for biologic activity of toceranib phosphate (Palladia^®) in solid tumours